Diabetes Res Clin PractWord文档下载推荐.docx
- 文档编号:8234250
- 上传时间:2023-05-10
- 格式:DOCX
- 页数:14
- 大小:85.16KB
Diabetes Res Clin PractWord文档下载推荐.docx
《Diabetes Res Clin PractWord文档下载推荐.docx》由会员分享,可在线阅读,更多相关《Diabetes Res Clin PractWord文档下载推荐.docx(14页珍藏版)》请在冰点文库上搜索。
∙4DepartmentofPharmacology,PoznanUniversityofMedicalSciences,Poznań,Poland.
∙5DepartmentofClinicalImmunology,PoznanUniversityofMedicalSciences,Poznań,Poland.
Abstract
AIMS:
Inrecentyearsinteresthasbeenfocusedonangiogenesisasaprocessinvolvedincoronaryarterydisease(CAD)anddiabeticdistalsensorimotorpolyneuropathy(DSPN).Recentstudieshavedemonstratedthepossibleangiogenesis-modulatingpotentialofalpha-lipoicacid(ALA)forDSPNandCAD.TheaimofourstudywastoinvestigatetheinfluenceofALAonserumangiogenicfactorsinpatientswithDM-2(type2diabetes)withCADandDSPN.
METHODS:
Sixtypatientswithtype2DM(T2DM)andCADand25non-diabeticsubjectswerestudied.ThirtypatientswithT2DM,CADandDSPNweregiven600mgofALAadayfor90days.VEGF,bFGF,MCP-1,angiogenin,IL-12andIL-10concentrationsintheseraweremeasuredbyflowcytometry.
RESULTS:
ALAsignificantlyincreasedVEGF,bFGFandIL-10anddecreasedMCP-1serumconcentrationsinpatientswithT2DMandCADandDSPN.VEGFandIL-10serumlevels,bothbeforeandafterALA-treatment,werehigherinthisgroupthaninT2DMandCADpatients,whilecirculatingbFGFwashigherandMCP-1serumlevellowerinpatientswithT2DMandCADandDSPNonlyinthepost-ALA-treatment,comparedtotheT2DMandCADgroup.
CONCLUSIONS:
ALAmayinfluenceangiogenesisintype2diabeticpatientsthroughaneffectonsomecirculatingfactorsincludingVEGF,bFGF,MCP-1andIL-10.
Copyright©
2014ElsevierIrelandLtd.Allrightsreserved.
KEYWORDS:
Alpha-lipoicacid;
IL-10;
MCP-1;
Type2diabetes;
VEGF;
bFGF
∙Abstract
Format
∙
Summary
Summary(text)
Abstract(text)
MEDLINE
XML
PMIDList
Apply
Sendto:
ChooseDestination
File
Clipboard
Collections
Order
MyBibliography
Citationmanager
∙Format
CreateFile
∙1selecteditem:
25535146
MeSHandOtherData
∙Subject
∙Additionaltext
Didn'
tgetthemessage?
Findoutwhy...
AddtoClipboard
AddtoCollections
Orderarticles
AddtoMyBibliography
Generateafileforusewithexternalcitationmanagementsoftware.
SeecommentinPubMedCommonsbelow
EurRevMedPharmacolSci.2014Dec;
18(23):
3715-9.
α-Lipoicacidtreatmentofagedtype2diabetesmellituscomplicatedwithacutecerebralinfarction.
ZhaoL1,HuFX.
∙1DepartmentofEndocrinology,HedongDistrictPeople'
sHospital,Linyi,China.liangzhaocn@.
OBJECTIVE:
Thisstudyaimstoevaluatetheefficacyandsafetyofα-lipoicacidinthetreatmentofagedtype2diabetesmellitus(T2DM)complicatedwithacutecerebralinfarction.
PATIENTSANDMETHODS:
90patientswererandomlydividedintotwogroups,onthebasisofconventionaltreatment.Theexperimentgroupwasadministratedwithα-lipoicacid,whileonlyVitaminCforthecontrolgroup,for3consecutiveweeks.Beforeandaftertheexperiment,superoxidedismutase(SOD),glutathioneperoxidase(GSH-Px)andmalondialdehyde(MDA)levelsweremeasuredandscoredwiththeNIHSS(NationalInstitutesofHealthStrokeScale),andthechangesofbloodglucose,insulinfunctionandotherindicatorswereobserved.
Afterthetreatment,theplasmaSODandGSH-Pxlevelsincreased,whileMDAdecreased(p<
0.05),withstatisticalsignificancewhencomparedwiththecontrolgroup(p<
0.01).NIHSSscore,bloodglucose,bloodlipidsandHOMA-IAoftheexperimentgroupdecreasedsignificantly(p<
0.01);
andnosignificantadversereactionswerefoundinbothgroups.
α-lipoicacidwassafeandeffectiveinthetreatmentofagedT2DMcomplicatedwithacutecerebralinfarction,significantlyreducingthepatient'
soxidativestress,bloodglucoseandlipidlevelsandbeingabletoimproveisletfunction.
Efficacyofα-lipoicacidindiabeticneuropathy.
PapanasN1,ZieglerD.
∙1DemocritusUniversityofThrace,SecondDepartmentofInternalMedicine,Alexandroupolis,Greece.
INTRODUCTION:
Neuropathyisaseriouscomplicationofdiabetes.Itsmanagementfocusesonglycaemiccontrol,multifactorialcardiovascularriskintervention,pathogenesis-orientedtherapy,andanalgesicswhereneeded.
AREASCOVERED:
Theobjectiveofthisreviewisassessmentofefficacyandsafetyofαlipoicacid(ALA,alsothiocticacid)inpathogenesis-orientedtreatmentofdiabeticneuropathy.ThemechanismsofactionofALAinexperimentaldiabeticneuropathyincludereductionofoxidativestressalongwithimprovementinnervebloodflow,nerveconductionvelocity,andseveralothermeasuresofnervefunction.Thereisampleevidencefromrandomised,double-blind,placebo-controlledclinicaltrialsandmeta-analyses,suggestingthatALAisefficaciousandsafeforthediabeticneuropathy,accomplishingclinicallymeaningfulimprovements.
EXPERTOPINION:
ALAisavaluabletherapeuticoptionfordiabeticneuropathy.Whencomparedwithcurrentlylicensedanalgesicdrugs,itisbettertolerated,hasamorerapidonsetofaction,andimprovesparaesthesiae,numbness,sensorydeficits,andmusclestrengthinadditiontoneuropathicpain.Inclinicalpractice,ALAmaybechoseninpatientswithearlyneuropathicdeficitsandsymptoms,inwhomclinicalimprovementismorelikely.ALAshouldalsobeconsideredwhencomorbiditiesrenderotheranalgesicslessappropriateorinthepresenceofcardiovascularautonomicneuropathy.
diabetesmellitus;
diabeticneuropathy;
efficacy;
oxidativestress;
thiocticacid;
treatment
Alpha-lipoicacidasapleiotropiccompoundwithpotentialtherapeuticuseindiabetesandotherchronicdiseases.
GomesMB1,NegratoCA2.
∙1DepartmentofInternalMedicine,DiabetesUnit,StateUniversityHospitalofRiodeJaneiro,Avenida28deSetembro,77,3°
andar,CEP20.551-030RiodeJaneiro,Brazil.
∙2DepartmentofInternalMedicine,Bauru'
sDiabeticsAssociation,17012-433Bauru,Sã
oPaulo,Brazil.
Alpha-lipoicacidisanaturallyoccurringsubstance,essentialforthefunctionofdifferentenzymesthattakepartinmitochondria'
soxidativemetabolism.Itisbelievedthatalpha-lipoicacidoritsreducedform,dihydrolipoicacidhavemanybiochemicalfunctionsactingasbiologicalantioxidants,asmetalchelators,reducersoftheoxidizedformsofotherantioxidantagentssuchasvitaminCandE,andmodulatorofthesignalingtransductionofseveralpathways.Theseabove-mentionedactionshavebeenshowninexperimentalstudiesemphasizingtheuseofalpha-lipoicacidasapotentialtherapeuticagentformanychronicdiseaseswithgreatepidemiologicalaswelleconomicandsocialimpactsuchasbraindiseasesandcognitivedysfunctionslikeAlzheimerdisease,obesity,nonalcoholicfattyliverdisease,burningmouthsyndrome,cardiovasculardisease,hypertension,sometypesofcancer,glaucomaandosteoporosis.Manyconflictingdatahavebeenfoundconcerningtheclinicaluseofalpha-lipoicacidinthetreatmentofdiabetesandofdiabetes-relatedchroniccomplicationssuchasretinopathy,nephropathy,neuropathy,woundhealinganddiabeticcardiovascularautonomicneuropathy.Themostfrequentclinicalconditioninwhichalpha-lipoicacidhasbeenstudiedwasinthemanagementofdiabeticperipheralneuropathyinpatientswithtype1aswelltype2diabetes.Consideringthatoxidativestress,aimbalancebetweenproandantioxidantswithexcessiveproductionofreactiveoxygenspecies,isafactorinthedevelopmentofmanydiseasesandthatalpha-lipoicacid,anaturalthiolantioxidant,hasbeenshowntohavebeneficialeffectsonoxidativestressparametersinvarioustissueswewrotethisarticleinordertomakeanup-to-datereviewofcurrentthinkingregardingalpha-lipoicacidanditsuseasanantioxidantdrugtherapyforamyriadofdiseasesthatcouldhavepotentialbenefitsfromitsuse.
Biochemicalaction;
Chronicdiseases;
Diabetesmellitus
JDiabetesComplications.2015Jan-Feb;
29
(1):
64-7.doi:
10.1016/j.jdiacomp.2014.09.011.Epub2014Sep30.
Thealpha-lipoicaciddecreasesurinarypodocalyxinexcretionintype2diabeticsbyinhibitingoxidativestressinvivo.
LinH1,YeS2,XuJ3,WangW3.
∙1DepartmentofEndocrinology,AnhuiProvincialHospitalAffiliatedtoAnhuiMedicalUniversity,Hefei,Anhui,China;
DepartmentofInternalMedicine,MaanshanMaternalandChildHealthCareCenter,Maanshan,Anhui,China.
∙2DepartmentofEndocrinology,AnhuiProvincialHospitalAffiliatedtoAnhuiMedicalUniversity,Hefei,Anhui,China.Electronicaddress:
ysd6406@.
∙3DepartmentofEndocrinology,AnhuiProvincialHospitalAffiliatedtoAnhuiMedicalUniversity,Hefei,Anhui,China.
ToobservetheeffectsofAlpha-lipoicacid(ALA)onoxidativestress(OS)invivoandurinarypodocalyxin(PCX,theglomerularpodocytemarkerprotein)excretionintype2diabeticsandexploreitspossibleprotectivemechanismsonglomerularpodocytes.
Thirty
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Diabetes Res Clin Pract
![提示](https://static.bingdoc.com/images/bang_tan.gif)